Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Rev. bras. anestesiol ; 65(3): 207-212, May-Jun/2015. tab, graf
Article in English | LILACS | ID: lil-748922


BACKGROUND AND OBJECTIVE: Postoperative pain treatment in mastectomy remains a major challenge despite the multimodal approach. The aim of this study was to investigate the analgesic effect of intravenous lidocaine in patients undergoing mastectomy, as well as the postoperative consumption of opioids. METHODS: After approval by the Human Research Ethics Committee of the Instituto de Medicina Integral Prof. Fernando Figueira in Recife, Pernambuco, a randomized, blind, controlled trial was conducted with intravenous lidocaine at a dose of 3 mg/kg infused over 1 h in 45 women undergoing mastectomy under general anesthesia. One patient from placebo group was. RESULTS: Groups were similar in age, body mass index, type of surgery, and postoperative need for opioids. Two of 22 patients in lidocaine group and three of 22 patients in placebo group requested opioid (p = 0.50). Pain on awakening was identified in 4/22 of lidocaine group and 5/22 of placebo group (p = 0.50); in the post-anesthetic recovery room in 14/22 and 12/22 (p = 0.37) of lidocaine and placebo groups, respectively. Pain evaluation 24 h after surgery showed that 2/22 and 3/22 patients (p = 0.50) of lidocaine and placebo groups, respectively, complained of pain. CONCLUSION: Intravenous lidocaine at a dose of 3 mg/kg administered over a period of an hour during mastectomy did not promote additional analgesia compared to placebo in the first 24 h, and has not decreased opioid consumption. However, a beneficial effect of intravenous lidocaine in selected and/or other therapeutic regimens patients cannot be ruled out. .

JUSTIFICATIVA E OBJETIVO: O tratamento da dor pós-operatória em mastectomia continua sendo um grande desafio apesar da abordagem multimodal. O objetivo deste estudo foi investigar o efeito analgésico da lidocaína intravenosa em pacientes submetidas a mastectomia, como também, o consumo de opioide pós-operatório. MÉTODOS: Após aprovação pelo comitê de ética e pesquisa em seres humanos do Instituto de Medicina Integral Prof. Fernando Figueira em Recife - Pernambuco foi realizado ensaio clínico aleatório encoberto placebo controlado com lidocaína intravenosa na dose de 3 mg/kg infundida em uma hora, em 45 mulheres submetidas a mastectomia sob anestesia geral. Excluída uma paciente do grupo placebo. RESULTADOS: Os grupos foram semelhantes quanto à idade, índice de massa corpórea, tipo de intervenção cirúrgica e necessidade de opioide no pós-operatório. Solicitaram opioide 2/22 pacientes nos grupos da lidocaína e 3/22 placebo (p = 0,50). Identificada a dor ao despertar em 4/22 no grupo lidocaína e 5/22 (p = 0,50) no grupo placebo; na sala de recuperação pós-anestésica em 14/22 e 12/22 (p = 0,37) nos grupos lidocaína e placebo respectivamente. Ao avaliar a dor 24 horas após o procedimento cirúrgico 3/22 e 2/22 (p = 0,50) das pacientes relataram dor em ambos os grupos respectivamente. CONCLUSÃO: A lidocaína intravenosa na dose de 3mg/kg administrada em um período de uma hora no transoperatório de mastectomia não promoveu analgesia adicional em relação ao grupo placebo nas primeiras 24 horas e não diminuiu o consumo de opioide. Contudo, um efeito benéfico da lidocaína intravenosa em pacientes selecionadas e/ou em outros regimes terapêuticos não pode ser descartado. .

JUSTIFICACIÓN Y OBJETIVO: El tratamiento del dolor postoperatorio en la mastectomía continúa siendo un gran reto a pesar del abordaje multimodal. El objetivo de este estudio fue investigar el efecto analgésico de la lidocaína intravenosa en pacientes sometidas a mastectomía, así como el consumo postoperatorio de opiáceos. MÉTODOS: Después de la aprobación por el Comité de Ética e Investigación en seres humanos del Instituto de Medicina Integral Prof. Fernando Figueira, en Recife, Pernambuco, se realizó un ensayo clínico aleatorizado, encubierto, placebo controlado con lidocaína intravenosa en una dosis de 3 mg/kg infundida en una hora, en 45 mujeres sometidas a mastectomía bajo anestesia general. Una paciente del grupo placebo fue excluida. RESULTADOS: Los grupos fueron similares en cuanto a la edad, índice de masa corporal, tipo de intervención quirúrgica y necesidad de opiáceos en el postoperatorio. Solicitaron opiáceos 2/22 pacientes en los grupos de la lidocaína y 3/22 placebo (p = 0,50). Fue identificado el dolor al despertar en 4/22 en el grupo lidocaína y 5/22 (p = 0,50) en el grupo placebo; en la sala de recuperación postanestésica en 14/22 y 12/22 (p = 0,37) en los grupos lidocaína y placebo, respectivamente. Al calcular el dolor 24 h después del procedimiento quirúrgico 3/22 y 2/22 (p = 0,50) de las pacientes relataron dolor en ambos grupos respectivamente. CONCLUSIÓN: La lidocaína intravenosa en una dosis de 3 mg/kg administrada en un período de una hora en el transoperatorio de mastectomía no generó analgesia adicional con relación al grupo placebo en las primeras 24 h y no disminuyó el consumo de opiáceos. Sin embargo, no puede ser descartado un efecto beneficioso de la lidocaína intravenosa en pacientes seleccionadas y/o en otros regímenes terapéuticos. .

Humans , Metapneumovirus/genetics , Transcription, Genetic , Viral Proteins/chemistry , Amino Acid Sequence , Adenosine Monophosphate/metabolism , Crystallography, X-Ray , DNA , Edetic Acid/pharmacology , Molecular Dynamics Simulation , Molecular Sequence Data , Protein Binding , Protein Conformation , Protein Multimerization , Protein Stability , Protein Subunits/chemistry , RNA, Viral/metabolism , RNA, Viral/ultrastructure , Scattering, Small Angle , Solutions , Solvents , Viral Proteins/metabolism , Viral Proteins/ultrastructure , Zinc Fingers
Indian J Exp Biol ; 2015 Feb; 53(2): 67-74
Article in English | IMSEAR | ID: sea-158377


The catabolism of fungal 4-aminobutyrate (GABA) occurs via succinic semialdehyde (SSA). Succinic semialdehyde dehydrogenase (SSADH) from the acidogenic fungus Aspergillus niger was purified from GABA grown mycelia to the highest specific activity of 277 nmol min-1 mg-1, using phenyl Sepharose and DEAE Sephacel chromatography. The purified enzyme was specific for its substrates SSA and NAD+. The substrate inhibition observed with SSA was uncompetitive with respect to NAD+. While product inhibition by succinate was not observed, NADH inhibited the enzyme competitively with respect to NAD+ and noncompetitively with respect to SSA. Dead-end inhibition by AMP and p-hydroxybenzaldehyde (pHB) was analyzed. The pHB inhibition was competitive with SSA and uncompetitive with NAD+; AMP competed with NAD+. Consistent with the kinetic data, a sequential, ordered Bi Bi mechanism is proposed for this enzyme.

Adenosine Monophosphate/metabolism , Adenosine Monophosphate/pharmacology , Aspergillus niger/enzymology , Aspergillus niger/metabolism , Benzaldehydes/metabolism , Benzaldehydes/pharmacology , Binding, Competitive , Biocatalysis/drug effects , Fungal Proteins/isolation & purification , Fungal Proteins/metabolism , Kinetics , Mycelium/enzymology , Mycelium/metabolism , NAD/metabolism , NAD/pharmacology , Protein Binding , Substrate Specificity , Succinate-Semialdehyde Dehydrogenase/isolation & purification , Succinate-Semialdehyde Dehydrogenase/metabolism , gamma-Aminobutyric Acid/analogs & derivatives , gamma-Aminobutyric Acid/metabolism , gamma-Aminobutyric Acid/pharmacology
Arq. bras. cardiol ; 75(2): 97-105, Aug. 2000. tab, graf
Article in Portuguese, English | LILACS | ID: lil-269929


OBJECTIVE: Studies have demonstrated that methylxanthines, such as caffeine, are A1 and A2 adenosine receptor antagonists found in the brain, heart, lungs, peripheral vessels, and platelets. Considering the high consumption of products with caffeine in their composition, in Brazil and throughout the rest of the world, the authors proposed to observe the effects of this substance on blood pressure and platelet aggregation. METHODS: Thirteen young adults, ranging from 21 to 27 years of age, participated in this study. Each individual took 750mg/day of caffeine (250mg tid), over a period of seven days. The effects on blood pressure were analyzed through the pressor test with handgrip, and platelet aggregation was analyzed using adenosine diphosphate, collagen, and adrenaline. RESULTS: Diastolic pressure showed a significant increase 24 hours after the first intake (p<0.05). This effect, however, disappeared in the subsequent days. The platelet aggregation tests did not reveal statistically significant alterations, at any time during the study. CONCLUSION: The data suggest that caffeine increases diastolic blood pressure at the beginning of caffeine intake. This hypertensive effect disappears with chronic use. The absence of alterations in platelet aggregation indicates the need for larger randomized studies.

Humans , Male , Female , Adult , Blood Pressure/drug effects , Caffeine/adverse effects , Central Nervous System Stimulants/adverse effects , Phosphodiesterase Inhibitors/adverse effects , Platelet Aggregation/drug effects , Adenosine Diphosphate/adverse effects , Adenosine Monophosphate/metabolism , Analysis of Variance , Collagen/adverse effects , Epinephrine/adverse effects , Hypertension/chemically induced , Receptors, Purinergic P1/antagonists & inhibitors
Arch. Inst. Cardiol. Méx ; 57(4): 273-8, jul.-ago. 1987. tab
Article in Spanish | LILACS | ID: lil-61232


Para estudiar el mecanismos de acción del AMP en el nodo A-V, se estudiaron 10 pacientes con taquicardia supraventricular por re-entrada (TVS) que incluía el nodo AV en su circuito.. El promedio de edad fue 32.8 + ou - 11.1 años. La taquicardia se indujo por estimulación auricular programada y se realizaron registros electrofisiológicos intracavitarios en todos los casos. En la primera etapa la administración de AMP suprimió la arrtmia en todos los casos en un tiempo promedio de 15.2 + ou - 2.6 seg., con una dosis de 0.095 + ou - 0.037mg/kg. En la segunda etapa la administración de atropina (0.04mg/kg.) no impidió la supresión de la arritmia. La dosis de AMP fue 0.122 + ou - 0.045mg/kg (P3NDS) y el tiempo promedio 16.2 + ou - 2.2 (p=NDS). En la tercera etapa: la administración de AMP no interrumpió la arritmia inducida bajo el efecto de atropina y aminofilina (4mg/kg) en 8 de los pacientes. En uno de los restantes la dosis necesarias fue 0.250mg/kg., y en el otro fue 0.075mg/kg. No hubo efectos colaterales graves. Se demuestra que la acción del AMP está mediada por estimulación agonista de receptores purinérgicos en el nodo AV

Adolescent , Adult , Humans , Male , Female , Adenosine Monophosphate/therapeutic use , Aminophylline/therapeutic use , Atropine/therapeutic use , Tachycardia, Supraventricular/drug therapy , Adenosine Monophosphate/metabolism , Aminophylline/metabolism , Arrhythmias, Cardiac/drug therapy , Atropine/metabolism , Clinical Trials as Topic , Mexico , Physical Stimulation